chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 69.0
Sex: F
Vaccine: UNK
Symptoms: Underdose
Clinical narrative: High dose annual flu vaccine no longer available. Patient was informed of differences between high dose flu formulation and 'regular' dose (for under 65yo) and consented to receipt of lower dose formulation of annual flu vaccine.
Age: 74.0
Sex: M
Vaccine: FLU4
Symptoms: Unevaluable event
Clinical narrative: High dose annual flu vaccine no longer available. Patient was informed of differences between high dose flu formulation and 'regular' dose (for under 65yo) and consented to receipt of lower dose formulation of annual flu vaccine.
Age: 31.0
Sex: F
Vaccine: UNK
Symptoms: Ageusia, Anosmia, Dizziness, Dyspnoea, Epistaxis
Clinical narrative: I'm on day 3 of very congested running noise noise bleeds never remember ever having one ever before fevered hot and cold sweats arm sore red and hot to touch chest congestion light headed dizzy bad sore throat and head aches
Age: 31.0
Sex: F
Vaccine: UNK
Symptoms: Feeling of body temperature change, Headache, Hyperhidrosis, Injection site erythema, Injection site swelling
Clinical narrative: I'm on day 3 of very congested running noise noise bleeds never remember ever having one ever before fevered hot and cold sweats arm sore red and hot to touch chest congestion light headed dizzy bad sore throat and head aches
Age: 31.0
Sex: F
Vaccine: UNK
Symptoms: Oropharyngeal pain, Pain, Pain in extremity, Pyrexia, Respiratory tract congestion
Clinical narrative: I'm on day 3 of very congested running noise noise bleeds never remember ever having one ever before fevered hot and cold sweats arm sore red and hot to touch chest congestion light headed dizzy bad sore throat and head aches
Age: 31.0
Sex: F
Vaccine: UNK
Symptoms: Rhinorrhoea
Clinical narrative: I'm on day 3 of very congested running noise noise bleeds never remember ever having one ever before fevered hot and cold sweats arm sore red and hot to touch chest congestion light headed dizzy bad sore throat and head aches
Age: 66.0
Sex: F
Vaccine: RSV
Symptoms: Laryngospasm
Clinical narrative: Laryngsoasm
Sex: F
Vaccine: PNC20
Symptoms: Death, Drug ineffective, Pneumonia
Clinical narrative: pneumonia; pneumonia; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A female patient received pneumococcal 20-val conj vac (dipht crm197 protein) (PREVNAR 20), as dose number unknown, single (Batch/Lot number: unknown) for immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PNEUMONIA (death, medically significant), DRUG INEFFECTIVE (death, medically significant), outcome "fatal" and all described as "pneumonia". Reporter's mom (patient) got the vaccine and died from pneumonia.  The patient date of death was unknown. Reported cause of death: "pneumonia". It was not reported if an autopsy was performed.  The information on the batch/lot number for pneumococcal 20-val conj vac (dipht crm197 protein), pneumococcal 20-val conj vac (dipht crm197 protein)  has been requested and will be submitted if and when received.; Reported Cause(s) of Death: pneumonia
Sex: F
Vaccine: COVID19
Symptoms: Paralysis, Thrombosis
Clinical narrative: Neighbour lady had a blood clot in her back and was paralyzed from her waist down two weeks after her first shot; Neighbour lady had a blood clot in her back and was paralyzed from her waist down two weeks after her first shot; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP).  A female patient received bnt162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: THROMBOSIS (medically significant), PARALYSIS (medically significant), all with latency 2 weeks after the suspect product(s) administration, outcome "unknown" and all described as "Neighbour lady had a blood clot in her back and was paralyzed from her waist down two weeks after her first shot". Clinical course: Reporter reported that her neighbour lady had a blood clot in her back and was paralyzed from her waist down two weeks after her first shot. She was now in a nursing home.  The information on the batch/lot number for bnt162b2 omi xbb.1.5 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021192614 same reporter/drug, different patient/events;
Sex: F
Vaccine: COVID19
Symptoms: Pulmonary thrombosis, Respiratory arrest
Clinical narrative: Blood clots in her lungs; Respiratory arrest; This is a spontaneous report received from a contactable reporter (Consumer or other non HCP), Program ID.  A female patient (not pregnant) received bnt162b2 (BNT162B2), as dose 2, single (Batch/Lot number: unknown) for COVID-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (dose 1, single; lot number: unknown), for COVID-19 immunization. The following information was reported: The spouse reported that his wife (patient) died after receiving her second shot of Pfizer's vaccine. She spent weeks in the hospital for blood clots in her lungs. She died a few months later of respiratory arrest. Her reaction to the vaccine was reported to VAERS and they were told to report to CICP. Their time limit ran out waiting for all the doctors and hospital reports. So they have been left with no choice but to start legal action against Pfizer. The outcome of event "Respiratory arrest" was fatal while the outcome of event "Blood clots in her lungs" was unknown. The patient date of death was unknown. Reported cause of death: "Respiratory arrest". It was not reported if an autopsy was performed.  The information on the batch/lot number for bnt162b2 has been requested and will be submitted if and when received.; Reported Cause(s) of Death: Respiratory arrest
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test, Vaccination failure
Clinical narrative: COVID test Positive; COVID test Positive; This is a spontaneous report received from contactable reporter(s) (Nurse). The reporter is the patient.  A 64-year-old female patient received bnt162b2 (BNT162B2), on 23Feb2021 as dose 1, single (Lot number: EL3249), in upper left arm and on 16Mar2021 as dose 2, single (Lot number: FF8839) at the age of 63 years, in upper left arm for covid-19 immunisation. The patient's relevant medical history included: "MS", start date: Aug1996 (ongoing); "Anxiety" (ongoing). Patient's family medical history included heart disease. Concomitant medication(s) included: ZOLOFT taken for anxiety, start date: 1996 (ongoing). The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset Jul2021, outcome "unknown" and all described as "COVID test Positive". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Jul2021) Positive.; Sender's Comments: Based on available information, a lack of efficacy (Vaccination failure and COVID-19) with the suspect vaccine BNT162B2 in this patient cannot be completely excluded.,Linked Report(s) : US-PFIZER INC-202300319238 Same patient/Vaccine,different event,different vaccine dose;
Age: 1.0
Sex: M
Vaccine: HIBV
Symptoms: Expired product administered
Clinical narrative: expired ACT HIB vaccine was administered to patient with no reported adverse event; Initial information received on 17-Oct-2023 regarding an unsolicited valid non-serious case received from a other health professional.  This case involves a 1 years old male patient who was administered an expired Hib (Prp/T) Vaccine [Act-Hib] was administered to patient with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included hepatitis a vaccine (hepatitis a) for immunisation; measles vaccine, mumps vaccine, rubella vaccine (mmr) for immunisation; and varicella zoster vaccine (varicella vaccine) for immunisation.  On 16-Oct-2023, the patient received 0.5 ml (Dose 4) of suspect HIB (PRP/T) VACCINE Powder and solvent for solution for injection (lot number: UJ784AB, Expiry date: 08-Oct-2023) (Strength: standard) (Frequency: once) via unknown route in unknown administration site for immunization.  On 16-Oct-2023 the patient was administered an expired Hib (Prp/T) Vaccine [Act-Hib] was administered to patient with no reported adverse event (expired product administered) (latency: same day).  It was reported, Compliance Specialist called from doctor`s office where an expired ACT HIB vaccine was administered to patient. This inquiry was submitted since an expired dose was given to a patient.  Action taken: not applicable.  Outcome: Unknown    This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 6.0
Sex: M
Vaccine: MMR
Symptoms: Circumstance or information capable of leading to medication error, Extra dose administered, No adverse event
Clinical narrative: No additional adverse events; Inbound call from nurse calling to report AE for MMR-II that was inadvertently given a second time within two weeks.  Nurse states that they misread the chart and administered a second dose of MMR-II two weeks after patient already received a dose on; This spontaneous report was received from a registered nurse concerning to a 6-year-old male patient. The patient's concurrent conditions, medical history, concomitant therapies and previous drugs reactions or allergies were not provided.     On 19-OCT-2023, the patient was inadvertenly vaccinated with the second dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(rHA) (M-M-R II) at a dose of 0.5 milliliter, lot # W025567 with an expiration date of 14-AUG-2024, for prophylaxis (strength, route of administration were not provided). The nurse stated that she misread the chart and administered a second dose of the vaccine two weeks after the patient already received the first dose (05-OCT-2023) (extra dose administered). No adverse event was reported.
Sex: U
Vaccine: VARZOS
Symptoms: Incomplete course of vaccination
Clinical narrative: not received 2nd dose yet; This non-serious case was reported by a consumer via call center representative and described the occurrence of incomplete course of vaccination in a 69-year-old patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received on 03 November 2019).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: not received 2nd dose yet). The outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt Date: 25-OCT-2023 and 31-OCT-2023 The patient reported that he/she would like to start the two shot regimen for Shingrix. However the pharmacy said that patient received the first dose back on November 03, 2019. The patient stated that he/she disputed this since his/her insurance at the time had no record of the Zoster immunization, and it did not show up on the state vaccine data base. The patient did remember receiving a flu shot that day and specifically refusing the Shingrix vaccine due to the expense and waiting for new insurance coverage the following year. In fact the clerk handed back the patient's paperwork and supposedly canceled that shot. They do have a record of patinet's flu vaccine that day. The patient questioned can he/she safely start the Shingrix inoculations four years later with dose 1 and then dose 2 or was there a lab test to be verified if te patient had the antibodies still around and the patient should only receive one Shingrix vaccine. The patient's primary care physician said he/she should be ok to start the series as if he/she had or had not received the vaccine back on November 03, 2019. Till the time of reporting, the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination. The reporter consented to follow up.
Sex: F
Vaccine: VARZOS
Symptoms: Incomplete course of vaccination
Clinical narrative: not received 2nd dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 72-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received on an unknown date).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: not received 2nd dose). The outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt Date: 25-OCT-2023 A pharmacist reported that a female patient received the 1st dose of Shingrix several years ago and was late for the 2nd dose. The reporter consented to follow up. The Healthcare professional did not have exact vaccination details of initial dose. Till the time of reporting, the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination. The Healthcare professional consented to follow up via email.
Sex: M
Vaccine: RSV
Symptoms: Extra dose administered
Clinical narrative: the administration of a second dose of Arexvy to a patient; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a 69-year-old male patient who received RSVPreF3 adjuvanted (Arexvy) (batch number g2mg3, expiry date 24-FEB-2025) for prophylaxis.   Concomitant products included RSV VACCINE PROT. SUBUNIT PREF3 (AREXVY).   In OCT-2023, the patient received the 2nd dose of Arexvy (intramuscular). In OCT-2023, an unknown time after receiving Arexvy, the patient experienced extra dose administered (Verbatim: the administration of a second dose of Arexvy to a patient). The outcome of the extra dose administered was unknown.   Additional Information: GSK receipt date: 25-Oct-2023 The pharmacist asked for information regarding this situation.  Permission to follow up was not requested during the call. The patient received 2nd dose of Arexvy, which led to extra dose administered
Sex: U
Vaccine: VARZOS
Symptoms: Headache, Neuralgia
Clinical narrative: neuralgia; severe headache; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of neuralgia in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced neuralgia (Verbatim: neuralgia) and headache (Verbatim: severe headache). The outcome of the neuralgia and headache were unknown.   It was unknown if the reporter considered the neuralgia and headache to be related to Shingrix.     It was unknown if the company considered the neuralgia and headache to be related to Shingrix.   Additional Information: GSK Receipt Date: 25-OCT-2023 The reporter did not consent to follow-up.
Age: 70.0
Sex: F
Vaccine: VARZOS
Symptoms: Expired product administered
Clinical narrative: an expired dose of Shingrix was administered to a patient; This non-serious case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a 70-year-old female patient who received Herpes zoster (Shingrix) (expiry date 12-OCT-2023) for prophylaxis.   On 25-OCT-2023, the patient received Shingrix. On 25-OCT-2023, an unknown time after receiving Shingrix, the patient experienced expired vaccine used (Verbatim: an expired dose of Shingrix was administered to a patient). The outcome of the expired vaccine used was unknown.   Additional Information: GSK Receipt Date - 25-OCT-2023 The pharmacy intern reported that an expired dose of Shingrix was administered to a patient, which led to expired vaccine used. The reporter consented to follow up.
Sex: U
Vaccine: HEP
Symptoms: Product storage error
Clinical narrative: Engerix B vaccines experienced a freezing temperature excursions; This non-serious case was reported by a nurse via call center representative and described the occurrence of incorrect storage of drug in a patient who received HBV (Engerix B) (batch number 9452S, expiry date 14-SEP-2025) for prophylaxis.   On an unknown date, the patient received Engerix B. On an unknown date, an unknown time after receiving Engerix B, the patient experienced incorrect storage of drug (Verbatim: Engerix B vaccines experienced a freezing temperature excursions). The outcome of the incorrect storage of drug was unknown.   Additional Information: GSK Receipt Date: 26-OCT-2023 The nurse reported that Engerix B vaccines experienced a freezing temperature excursions that occurred between 20 September 2023 and 05 October 2023. She believed that there were probably three doses administered after the freezing excursion, which led to incorrect storage of drug. But she had not yet performed an audit so did not have any patient information or dates of administration. The reporter consented to follow up. The vaccine administration facility was the same as primary reporter.
Sex: U
Vaccine: FLU4
Symptoms: Incorrect route of product administration
Clinical narrative: Fluarix QIV was administered subcutaneously to more than one patient; This non-serious case was reported by a nurse via call center representative and described the occurrence of intramuscular formulation administered by other route in an unspecified number of patients who received Flu Seasonal QIV Dresden (Fluarix Quadrivalent 2023-2024 season) (batch number PM35E, expiry date 30-JUN-2024) for prophylaxis.   On an unknown date, the patient received Fluarix Quadrivalent 2023-2024 season (subcutaneous) .5 ml. On an unknown date, an unknown time after receiving Fluarix Quadrivalent 2023-2024 season, the patient experienced intramuscular formulation administered by other route (Verbatim: Fluarix QIV was administered subcutaneously to more than one patient). The outcome of the intramuscular formulation administered by other route was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt date: 26-OCT-2023 The nurse reported to inform that Fluarix Quadrivalent was administered subcutaneously to more than one patient. The reporter didn't provide an exact number of patients, as that information was not available at the moment. The reporter consented to follow up.  The Vaccine Administration Facility was the same as Primary Reporter.
Sex: F
Vaccine: FLUX, VARZOS
Symptoms: Pain
Clinical narrative: developed pain 1 week later that has not resolved.; This non-serious case was reported by a consumer via call center representative and described the occurrence of pain in a infant female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included INFLUENZA VACCINE (FLU VACCINE (NAME UNKNOWN)) for prophylaxis.   The patient's past medical history included shoulder injury (MVA Left shoulder injury) and automobile accident (a motor vehicle accident May 2023). Previously administered products included Flu Vaccine.   On 29-SEP-2023, the patient received the 1st dose of Shingrix (intramuscular, left deltoid) and FLU VACCINE (NAME UNKNOWN) (right deltoid). In OCT-2023, 1 week after receiving Shingrix, the patient experienced pain (Verbatim: developed pain 1 week later that has not resolved.). The outcome of the pain was not resolved.   It was unknown if the reporter considered the pain to be related to Shingrix.     It was unknown if the company considered the pain to be related to Shingrix.   Additional Information: GSK receipt date: 26-OCT-2023 The customer reported that she was in a motor vehicle accident May 2023 and sustained a left shoulder injury.  The patient received her 1st Shingrix vaccine and developed pain 1 week later that has not resolved.   She received her flu vaccine at the same visit. It was unknown if the reporter considered the pain to be related to Flu vaccine. The reporter did not consent to follow-up.
Age: 74.0
Sex: M
Vaccine: PNC20
Symptoms: Death
Clinical narrative: Patient expired on 11/2; found at home by law enforcement
Age: 45.0
Sex: F
Vaccine: FLU4
Symptoms: Disorientation, Dizziness, Foetal heart rate increased, Migraine, Nausea
Clinical narrative: Migraine Dizziness Rapid heart rate (110-122) Disorientation Nausea/vomiting
Age: 45.0
Sex: F
Vaccine: FLU4
Symptoms: Vomiting
Clinical narrative: Migraine Dizziness Rapid heart rate (110-122) Disorientation Nausea/vomiting
Age: 11.0
Sex: F
Vaccine: MENB
Symptoms: Wrong product administered
Clinical narrative: Medical Assistant gave the wrong vaccine to patient. Meningitis B was given to patient instead of Meningitis (Menveo). Manager, Provider,  Team Lead and Health Department were all informed once discovered.  Parent has since be informed.
Age: 1.0
Sex: F
Vaccine: HEPA, PNC15, VARCEL
Symptoms: Injection site erythema, Injection site swelling, Injection site warmth
Clinical narrative: Warmth, redness, & swelling of injection site occurred within 1 minute of administration. 4mL Benadryl (12.5mg/5mL) given po 5 min after the reaction began. Ice pack given to hold on the site. No respiratory distress, vomiting, or wheezing occurred. Redness & swelling of the site improved within 30min of adm. Benadryl.
Sex: M
Vaccine: DTAP, FLUC4, IPV, MMR, VARCEL
Symptoms: Erythema, Induration
Clinical narrative: Local area of erythema and induration 5cm x 6cm topical Hydrocortisone cream to left arm
Age: 73.0
Sex: F
Vaccine: RSV
Symptoms: Chills, Urticaria
Clinical narrative: Patient received RSV Abrysvo vaccine and experienced hives (over entire body, except face) and chills the following day. Patient reported using Benadryl by mouth and topical to treat hives and symptoms went away after two days.
Sex: M
Vaccine: FLU4
Symptoms: Syringe issue, Underdose
Clinical narrative: vaccine leaked out sides of syringe when administering
Sex: M
Vaccine: COVID19
Symptoms: Blood pressure immeasurable, Dizziness, Electrocardiogram ambulatory abnormal, Extrasystoles, Presyncope
Clinical narrative: Received the new mRNA COVID immunization/booster (my sixth) on 10/2/23. On 10/6 my BP was hard to measure accurately as I was skipping at least every fourth beat with PVCs. On 10/7 I applied a Zio XT heart monitor that my cardiologist had prescribed for me. I wore it for a week during which time I had five more days of significant dizziness and presyncope. When the Zio monitor was analyzed, I had experienced a PVC burden of 25.9%. I continued to have episodes of dizziness from 10/12 through 10/23. Previous history: I had had COVID in 12/22 and during the days that I was most ill, I had fainted (from standing to floor) three times. I received no medication during my illness but did think I had responded to Liquid IV so my cardiologist thought perhaps I was simply dehydrated. I now believe it was the viral effect of COVID on my heart as was demonstrated 10 months later with the mRNA COVID immunization. I have a new Zio XT monitor that I will be applying today (11/2/23) and it will be worn for 14 days. Now that the dizziness is gone, my electrophysiologist cardiologist want to reassess my PVC burden.
Sex: M
Vaccine: COVID19
Symptoms: Ventricular extrasystoles
Clinical narrative: Received the new mRNA COVID immunization/booster (my sixth) on 10/2/23. On 10/6 my BP was hard to measure accurately as I was skipping at least every fourth beat with PVCs. On 10/7 I applied a Zio XT heart monitor that my cardiologist had prescribed for me. I wore it for a week during which time I had five more days of significant dizziness and presyncope. When the Zio monitor was analyzed, I had experienced a PVC burden of 25.9%. I continued to have episodes of dizziness from 10/12 through 10/23. Previous history: I had had COVID in 12/22 and during the days that I was most ill, I had fainted (from standing to floor) three times. I received no medication during my illness but did think I had responded to Liquid IV so my cardiologist thought perhaps I was simply dehydrated. I now believe it was the viral effect of COVID on my heart as was demonstrated 10 months later with the mRNA COVID immunization. I have a new Zio XT monitor that I will be applying today (11/2/23) and it will be worn for 14 days. Now that the dizziness is gone, my electrophysiologist cardiologist want to reassess my PVC burden.
Sex: F
Vaccine: COVID19
Symptoms: Blood pressure increased, Immunisation reaction
Clinical narrative: Increased blood pressure from Pfizer Covid vaccine reported to Dr October 20, 2021 at office visit. September 15, 2022 prescribed amlodipine 5mg by Dr.
Sex: U
Vaccine: COVID19
Symptoms: Chills, Heart rate increased, Impaired work ability, Injection site reaction, Musculoskeletal stiffness
Clinical narrative: stiffness of upper right arm, chills (difficulty speaking, difficulty typing,) fever up to 103F, elevated pulse (highest noted 118 bpm by pulse oximeter but did not monitor entire time.)   Treated with Aleve, Tylenol, rest, drinking water, turning thermostat to > 70F, wearing multiple layers of clothing. Temperature was below 100F by 10:30 PM. Fitbit tracker calculates I had 279 Zone Minutes during the event. I was lying or sitting on the couch after 1:15 PM and did not exert myself.  Clocked out of work approximately 12:57. I answer phones and type during my shift and was unable to perform essential tasks related to my duties.
Sex: U
Vaccine: COVID19
Symptoms: Pyrexia, Speech disorder
Clinical narrative: stiffness of upper right arm, chills (difficulty speaking, difficulty typing,) fever up to 103F, elevated pulse (highest noted 118 bpm by pulse oximeter but did not monitor entire time.)   Treated with Aleve, Tylenol, rest, drinking water, turning thermostat to > 70F, wearing multiple layers of clothing. Temperature was below 100F by 10:30 PM. Fitbit tracker calculates I had 279 Zone Minutes during the event. I was lying or sitting on the couch after 1:15 PM and did not exert myself.  Clocked out of work approximately 12:57. I answer phones and type during my shift and was unable to perform essential tasks related to my duties.
Age: 27.0
Sex: F
Vaccine: HEP, VARCEL
Symptoms: Expired product administered, No adverse event
Clinical narrative: Varivax was expired 9/9/23 but administered on 11/3/23. No apparent harm to vaccine recipient.
Age: 15.0
Sex: M
Vaccine: MNQ
Symptoms: Inappropriate schedule of product administration, No adverse event
Clinical narrative: Menveo given at inappropriate interval. No immediate adverse reaction.
Age: 14.0
Sex: F
Vaccine: MNQ
Symptoms: Inappropriate schedule of product administration, No adverse event
Clinical narrative: Menveo given at inappropriate interval. No immediate adverse reaction.
Age: 81.0
Sex: F
Vaccine: FLU4
Symptoms: Aberrant aortic arch, Angiogram cerebral abnormal, Aortic valve incompetence, Aphasia, Arteriogram carotid abnormal
Clinical narrative: WITHIN APPROXIMATELY FIVE HOURS OF RECEIVING FLUZONE HD QUADRIVALENT VACCINE, SINGLE DOSE SYRINGE, IM TO LEFT DELTOID ON 10/09/2023 AT 8:07AM AT THE DOCTOR'S OFFICE, PT'S HUSBAND NOTICED PT WAS DEMONSTRATING PERSONALITY CHANGES AND HAVING FULL BODY TREMORS. WITHIN MINUTES FROM THIS FINDING, PT BECAME APHASIC, CONFUSED AND DIAPHORETIC. SHE EXPERIENCED LOSS OF BLADDER CONTROL, MUSCULAR RIGIDITY AND GENERALIZED WEAKNESS.  FAMILY MEMBERS ADMINISTERED CHEWABLE ASPIRIN 81MG X 3 PO TO PT THEN TRANSPORTED HER BY PERSONAL VEHICLE TO ER. PT WAS ADMITTED TO THE HOSPITAL ON 10/09/2023 AT 7:39PM. HER TREATMENT INCLUDED IV ANTIBIOTICS, ROCEPHIN & VANCOMYCIN, IV ANTIVIRAL, ACYCLOVIR, ANTIPYRETICS,  IV FLUIDS, NS AT 75MLS PER HOUR, AND PT/OT/ST.
Age: 81.0
Sex: F
Vaccine: FLU4
Symptoms: Asthenia, Bacteriuria, CSF culture negative, Cerebral atrophy, Cerebral small vessel ischaemic disease
Clinical narrative: WITHIN APPROXIMATELY FIVE HOURS OF RECEIVING FLUZONE HD QUADRIVALENT VACCINE, SINGLE DOSE SYRINGE, IM TO LEFT DELTOID ON 10/09/2023 AT 8:07AM AT THE DOCTOR'S OFFICE, PT'S HUSBAND NOTICED PT WAS DEMONSTRATING PERSONALITY CHANGES AND HAVING FULL BODY TREMORS. WITHIN MINUTES FROM THIS FINDING, PT BECAME APHASIC, CONFUSED AND DIAPHORETIC. SHE EXPERIENCED LOSS OF BLADDER CONTROL, MUSCULAR RIGIDITY AND GENERALIZED WEAKNESS.  FAMILY MEMBERS ADMINISTERED CHEWABLE ASPIRIN 81MG X 3 PO TO PT THEN TRANSPORTED HER BY PERSONAL VEHICLE TO ER. PT WAS ADMITTED TO THE HOSPITAL ON 10/09/2023 AT 7:39PM. HER TREATMENT INCLUDED IV ANTIBIOTICS, ROCEPHIN & VANCOMYCIN, IV ANTIVIRAL, ACYCLOVIR, ANTIPYRETICS,  IV FLUIDS, NS AT 75MLS PER HOUR, AND PT/OT/ST.
Age: 81.0
Sex: F
Vaccine: FLU4
Symptoms: Chest X-ray abnormal, Computerised tomogram head abnormal, Confusional state, Contrast echocardiogram, Culture urine positive
Clinical narrative: WITHIN APPROXIMATELY FIVE HOURS OF RECEIVING FLUZONE HD QUADRIVALENT VACCINE, SINGLE DOSE SYRINGE, IM TO LEFT DELTOID ON 10/09/2023 AT 8:07AM AT THE DOCTOR'S OFFICE, PT'S HUSBAND NOTICED PT WAS DEMONSTRATING PERSONALITY CHANGES AND HAVING FULL BODY TREMORS. WITHIN MINUTES FROM THIS FINDING, PT BECAME APHASIC, CONFUSED AND DIAPHORETIC. SHE EXPERIENCED LOSS OF BLADDER CONTROL, MUSCULAR RIGIDITY AND GENERALIZED WEAKNESS.  FAMILY MEMBERS ADMINISTERED CHEWABLE ASPIRIN 81MG X 3 PO TO PT THEN TRANSPORTED HER BY PERSONAL VEHICLE TO ER. PT WAS ADMITTED TO THE HOSPITAL ON 10/09/2023 AT 7:39PM. HER TREATMENT INCLUDED IV ANTIBIOTICS, ROCEPHIN & VANCOMYCIN, IV ANTIVIRAL, ACYCLOVIR, ANTIPYRETICS,  IV FLUIDS, NS AT 75MLS PER HOUR, AND PT/OT/ST.
Age: 81.0
Sex: F
Vaccine: FLU4
Symptoms: Echocardiogram abnormal, Ejection fraction normal, Electrocardiogram normal, Hyperhidrosis, Laboratory test normal
Clinical narrative: WITHIN APPROXIMATELY FIVE HOURS OF RECEIVING FLUZONE HD QUADRIVALENT VACCINE, SINGLE DOSE SYRINGE, IM TO LEFT DELTOID ON 10/09/2023 AT 8:07AM AT THE DOCTOR'S OFFICE, PT'S HUSBAND NOTICED PT WAS DEMONSTRATING PERSONALITY CHANGES AND HAVING FULL BODY TREMORS. WITHIN MINUTES FROM THIS FINDING, PT BECAME APHASIC, CONFUSED AND DIAPHORETIC. SHE EXPERIENCED LOSS OF BLADDER CONTROL, MUSCULAR RIGIDITY AND GENERALIZED WEAKNESS.  FAMILY MEMBERS ADMINISTERED CHEWABLE ASPIRIN 81MG X 3 PO TO PT THEN TRANSPORTED HER BY PERSONAL VEHICLE TO ER. PT WAS ADMITTED TO THE HOSPITAL ON 10/09/2023 AT 7:39PM. HER TREATMENT INCLUDED IV ANTIBIOTICS, ROCEPHIN & VANCOMYCIN, IV ANTIVIRAL, ACYCLOVIR, ANTIPYRETICS,  IV FLUIDS, NS AT 75MLS PER HOUR, AND PT/OT/ST.
Age: 81.0
Sex: F
Vaccine: FLU4
Symptoms: Left ventricular hypertrophy, Lumbar puncture normal, Magnetic resonance imaging head normal, Muscle rigidity, Personality change
Clinical narrative: WITHIN APPROXIMATELY FIVE HOURS OF RECEIVING FLUZONE HD QUADRIVALENT VACCINE, SINGLE DOSE SYRINGE, IM TO LEFT DELTOID ON 10/09/2023 AT 8:07AM AT THE DOCTOR'S OFFICE, PT'S HUSBAND NOTICED PT WAS DEMONSTRATING PERSONALITY CHANGES AND HAVING FULL BODY TREMORS. WITHIN MINUTES FROM THIS FINDING, PT BECAME APHASIC, CONFUSED AND DIAPHORETIC. SHE EXPERIENCED LOSS OF BLADDER CONTROL, MUSCULAR RIGIDITY AND GENERALIZED WEAKNESS.  FAMILY MEMBERS ADMINISTERED CHEWABLE ASPIRIN 81MG X 3 PO TO PT THEN TRANSPORTED HER BY PERSONAL VEHICLE TO ER. PT WAS ADMITTED TO THE HOSPITAL ON 10/09/2023 AT 7:39PM. HER TREATMENT INCLUDED IV ANTIBIOTICS, ROCEPHIN & VANCOMYCIN, IV ANTIVIRAL, ACYCLOVIR, ANTIPYRETICS,  IV FLUIDS, NS AT 75MLS PER HOUR, AND PT/OT/ST.
Age: 81.0
Sex: F
Vaccine: FLU4
Symptoms: Pulmonary mass, Respiratory pathogen panel, Right aortic arch, Scan with contrast normal, Spinal X-ray normal
Clinical narrative: WITHIN APPROXIMATELY FIVE HOURS OF RECEIVING FLUZONE HD QUADRIVALENT VACCINE, SINGLE DOSE SYRINGE, IM TO LEFT DELTOID ON 10/09/2023 AT 8:07AM AT THE DOCTOR'S OFFICE, PT'S HUSBAND NOTICED PT WAS DEMONSTRATING PERSONALITY CHANGES AND HAVING FULL BODY TREMORS. WITHIN MINUTES FROM THIS FINDING, PT BECAME APHASIC, CONFUSED AND DIAPHORETIC. SHE EXPERIENCED LOSS OF BLADDER CONTROL, MUSCULAR RIGIDITY AND GENERALIZED WEAKNESS.  FAMILY MEMBERS ADMINISTERED CHEWABLE ASPIRIN 81MG X 3 PO TO PT THEN TRANSPORTED HER BY PERSONAL VEHICLE TO ER. PT WAS ADMITTED TO THE HOSPITAL ON 10/09/2023 AT 7:39PM. HER TREATMENT INCLUDED IV ANTIBIOTICS, ROCEPHIN & VANCOMYCIN, IV ANTIVIRAL, ACYCLOVIR, ANTIPYRETICS,  IV FLUIDS, NS AT 75MLS PER HOUR, AND PT/OT/ST.
Age: 81.0
Sex: F
Vaccine: FLU4
Symptoms: Swallow study, Tremor, Tricuspid valve incompetence, Ultrasound Doppler normal, Urinary incontinence
Clinical narrative: WITHIN APPROXIMATELY FIVE HOURS OF RECEIVING FLUZONE HD QUADRIVALENT VACCINE, SINGLE DOSE SYRINGE, IM TO LEFT DELTOID ON 10/09/2023 AT 8:07AM AT THE DOCTOR'S OFFICE, PT'S HUSBAND NOTICED PT WAS DEMONSTRATING PERSONALITY CHANGES AND HAVING FULL BODY TREMORS. WITHIN MINUTES FROM THIS FINDING, PT BECAME APHASIC, CONFUSED AND DIAPHORETIC. SHE EXPERIENCED LOSS OF BLADDER CONTROL, MUSCULAR RIGIDITY AND GENERALIZED WEAKNESS.  FAMILY MEMBERS ADMINISTERED CHEWABLE ASPIRIN 81MG X 3 PO TO PT THEN TRANSPORTED HER BY PERSONAL VEHICLE TO ER. PT WAS ADMITTED TO THE HOSPITAL ON 10/09/2023 AT 7:39PM. HER TREATMENT INCLUDED IV ANTIBIOTICS, ROCEPHIN & VANCOMYCIN, IV ANTIVIRAL, ACYCLOVIR, ANTIPYRETICS,  IV FLUIDS, NS AT 75MLS PER HOUR, AND PT/OT/ST.
Age: 81.0
Sex: F
Vaccine: FLU4
Symptoms: Urinary tract infection pseudomonal, Urine analysis abnormal, West Nile virus test negative, X-ray
Clinical narrative: WITHIN APPROXIMATELY FIVE HOURS OF RECEIVING FLUZONE HD QUADRIVALENT VACCINE, SINGLE DOSE SYRINGE, IM TO LEFT DELTOID ON 10/09/2023 AT 8:07AM AT THE DOCTOR'S OFFICE, PT'S HUSBAND NOTICED PT WAS DEMONSTRATING PERSONALITY CHANGES AND HAVING FULL BODY TREMORS. WITHIN MINUTES FROM THIS FINDING, PT BECAME APHASIC, CONFUSED AND DIAPHORETIC. SHE EXPERIENCED LOSS OF BLADDER CONTROL, MUSCULAR RIGIDITY AND GENERALIZED WEAKNESS.  FAMILY MEMBERS ADMINISTERED CHEWABLE ASPIRIN 81MG X 3 PO TO PT THEN TRANSPORTED HER BY PERSONAL VEHICLE TO ER. PT WAS ADMITTED TO THE HOSPITAL ON 10/09/2023 AT 7:39PM. HER TREATMENT INCLUDED IV ANTIBIOTICS, ROCEPHIN & VANCOMYCIN, IV ANTIVIRAL, ACYCLOVIR, ANTIPYRETICS,  IV FLUIDS, NS AT 75MLS PER HOUR, AND PT/OT/ST.
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: Abscess drainage, Abscess limb, Computerised tomogram abnormal, Culture wound, Incisional drainage
Clinical narrative: Discharge summary "Brief Summary of Hospital Stay: The patient is a 72-year-old male presenting to the emergency department with worsening leg abscess despite antibiotic therapy.  CT scan showed a large multiloculated abscess involving the subfascial gastrocnemius muscle and extending partly up into the subcutaneous tissues. Patient underwent incision and drainage of abscess on 11/1 with Dr. Noted surgical findings of copious purulent discharge with loculations.  Patient discharged in stable condition with additional keflex x 5 days. Wound culture results pending at discharge   Issues Requiring Follow Up: Routine post surgical wound check with Dr."
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: Muscle abscess, Purulent discharge, Subcutaneous abscess, Wound
Clinical narrative: Discharge summary "Brief Summary of Hospital Stay: The patient is a 72-year-old male presenting to the emergency department with worsening leg abscess despite antibiotic therapy.  CT scan showed a large multiloculated abscess involving the subfascial gastrocnemius muscle and extending partly up into the subcutaneous tissues. Patient underwent incision and drainage of abscess on 11/1 with Dr. Noted surgical findings of copious purulent discharge with loculations.  Patient discharged in stable condition with additional keflex x 5 days. Wound culture results pending at discharge   Issues Requiring Follow Up: Routine post surgical wound check with Dr."
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Dizziness, Dyspnoea
Clinical narrative: BP 220/110, dizziness, shortness of breath
Age: 88.0
Sex: M
Vaccine: COVID19
Symptoms: Oxygen saturation decreased, Pyrexia
Clinical narrative: fever, low Oxygen saturation (87%), BP 200/110
Age: 6.0
Sex: M
Vaccine: COVID19
Symptoms: Product administered to patient of inappropriate age, Wrong product administered
Clinical narrative: The patient is 6 years old but was given the 12+ shot.
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Flushing, Pain, Pyrexia, Swelling face
Clinical narrative: Per patient sha had fever 100.6 F. swelling and flushing (face). body aches
Age: 90.0
Sex: M
Vaccine: COVID19
Symptoms: Condition aggravated, General physical health deterioration
Clinical narrative: Sharp decline in total health beginning day after vaccine, very possibly could be general decline unrelated to vaccine. Pt requested we make report.
Age: 26.0
Sex: F
Vaccine: FLUC4
Symptoms: Headache, Injection site erythema, Injection site pain, Injection site pruritus, Injection site warmth
Clinical narrative: 10/31/2023@1452- flu vaccination. 17 hours post vaccination, pain, erythema, pruritus observed on injection site. Also tingling on left hand/fingers. On 11/2/2023, employee had headache, chest muscle tightness on the upper left location with continued localized erythema, warm to touch and pruritus. Left arm continued to be sore, with some still some tingling. 11/3/2023- Pruritus worsening.
Age: 26.0
Sex: F
Vaccine: FLUC4
Symptoms: Muscle tightness, Pain in extremity, Paraesthesia
Clinical narrative: 10/31/2023@1452- flu vaccination. 17 hours post vaccination, pain, erythema, pruritus observed on injection site. Also tingling on left hand/fingers. On 11/2/2023, employee had headache, chest muscle tightness on the upper left location with continued localized erythema, warm to touch and pruritus. Left arm continued to be sore, with some still some tingling. 11/3/2023- Pruritus worsening.
Age: 10.0
Sex: M
Vaccine: COVID19-2
Symptoms: Incorrect dose administered, No adverse event, Product administered to patient of inappropriate age
Clinical narrative: 10 years old and was given the adult dose of 0.5 instead of .25cc.  Talked to parent and child has no adverse reactions
Age: 1.25
Sex: M
Vaccine: PNC20
Symptoms: Expired product administered
Clinical narrative: Expired vaccine administered to patient.
Age: 0.5
Sex: F
Vaccine: PNC20
Symptoms: Expired product administered
Clinical narrative: Expired vaccine administered to patient.
Age: 32.0
Sex: F
Vaccine: RSV
Symptoms: Exposure during pregnancy, Injection site erythema, Nausea
Clinical narrative: Patient received vaccine at 36 w gestation EDD 11/28/2023. within 24 h after vaccine developed nausea and erythema to left arm at injection site persisting 48h after vaccination, without history of reactions to different historical vaccinations.
Age: 63.0
Sex: M
Vaccine: VARZOS
Symptoms: Fatigue, Influenza like illness, Pain, Pyrexia
Clinical narrative: flu like fever pain all over and tired
Age: 46.0
Sex: F
Vaccine: FLU4
Symptoms: Bursitis, Injected limb mobility decreased, Pain, Pain in extremity, Product administered at inappropriate site
Clinical narrative: The adverse event is related to the location the shot was administered. It was given very high on my left arm, almost the top of my shoulder. The nurse, was standing while I was seated. I realized he moved my sleeve up further on my shoulder, but I did not look when he did the injection. The band aid was place very high on my shoulder, higher than I have ever seen with previous vaccinations.  I felt more than the usual pain almost immediately and by the evening, my arm was throbbing and felt "frozen", where I could not move it independently. The pain was present from 10/10/23-10/16/23 where it subsided for approximately 2 days. On 10/19/23 the pain and inability to move my arm returned. I visited my orthopedic doctor (MD) on Monday 10/23/23 and was told it was Impingement syndrome resulting from improper vaccine administration causing bursitis and tendinitis. My shoulder was x-rayed and I was given a subacromial cortisone injection and told to return for follow-up on 12/6/23. On 11/2/23 my pain has not subsided, I contacted my doctor who prescribed DICLOFENAC SODIUM 50mg twice a day due to severe pain at night and in the morning. I am told to check in within a week if there is still no improvement to determine if an MRI is warranted.
Age: 46.0
Sex: F
Vaccine: FLU4
Symptoms: Rotator cuff syndrome, X-ray limb abnormal
Clinical narrative: The adverse event is related to the location the shot was administered. It was given very high on my left arm, almost the top of my shoulder. The nurse, was standing while I was seated. I realized he moved my sleeve up further on my shoulder, but I did not look when he did the injection. The band aid was place very high on my shoulder, higher than I have ever seen with previous vaccinations.  I felt more than the usual pain almost immediately and by the evening, my arm was throbbing and felt "frozen", where I could not move it independently. The pain was present from 10/10/23-10/16/23 where it subsided for approximately 2 days. On 10/19/23 the pain and inability to move my arm returned. I visited my orthopedic doctor (MD) on Monday 10/23/23 and was told it was Impingement syndrome resulting from improper vaccine administration causing bursitis and tendinitis. My shoulder was x-rayed and I was given a subacromial cortisone injection and told to return for follow-up on 12/6/23. On 11/2/23 my pain has not subsided, I contacted my doctor who prescribed DICLOFENAC SODIUM 50mg twice a day due to severe pain at night and in the morning. I am told to check in within a week if there is still no improvement to determine if an MRI is warranted.
Age: 66.0
Sex: M
Vaccine: FLU4, PNC20
Symptoms: Electrocardiogram, Pain in jaw, Tongue disorder
Clinical narrative: Vaccine given at 11:40 AM. Patients reports feeling jaw pain at 12:30PM. The next morning at 5:00AM patient states he began feeling thickness in the tongue. By 6:30 AM it was worse and he went to the Emergency Room. He was unable to communicate with the staff, but handed them the VIS statement on the vaccines. Patient states that they did an EKG but no other workup.
Age: 7.0
Sex: M
Vaccine: FLUN4
Symptoms: Eye swelling
Clinical narrative: Eye swelling evening of administration of Flumist- increase antihistamine dosing to twice a day if needed
Age: 57.0
Sex: M
Vaccine: COVID19-2
Symptoms: Acute kidney injury, Anti-glomerular basement membrane antibody, Antineutrophil cytoplasmic antibody negative, Antinuclear antibody negative, Biopsy kidney abnormal
Clinical narrative: The patient received a COVID vaccine at an outside facility, and the next day developed malaise and fevers, and then progressively orange urine over the ensuing 3 days, presented to our ED in acute renal failure and early hepatitis, over ensuing several days rapidly progressed to profound renal failure requiring HD and severe hepatitis. Renal biopsy confirms Rapidly Progressive Glomurulonephritis with crescents, however all serological testing is negative (negative ANA, ANCA, anti-GBM, etc).. We have no etiologic driver of the RPGN in terms of standard vasculitis or autoimmune testing.  On immunosuppressives.
Age: 57.0
Sex: M
Vaccine: COVID19-2
Symptoms: Chromaturia, Glomerulonephritis rapidly progressive, Haemodialysis, Hepatitis, Immunosuppressant drug therapy
Clinical narrative: The patient received a COVID vaccine at an outside facility, and the next day developed malaise and fevers, and then progressively orange urine over the ensuing 3 days, presented to our ED in acute renal failure and early hepatitis, over ensuing several days rapidly progressed to profound renal failure requiring HD and severe hepatitis. Renal biopsy confirms Rapidly Progressive Glomurulonephritis with crescents, however all serological testing is negative (negative ANA, ANCA, anti-GBM, etc).. We have no etiologic driver of the RPGN in terms of standard vasculitis or autoimmune testing.  On immunosuppressives.
Age: 57.0
Sex: M
Vaccine: COVID19-2
Symptoms: Malaise, Pyrexia, Renal failure, Serology test
Clinical narrative: The patient received a COVID vaccine at an outside facility, and the next day developed malaise and fevers, and then progressively orange urine over the ensuing 3 days, presented to our ED in acute renal failure and early hepatitis, over ensuing several days rapidly progressed to profound renal failure requiring HD and severe hepatitis. Renal biopsy confirms Rapidly Progressive Glomurulonephritis with crescents, however all serological testing is negative (negative ANA, ANCA, anti-GBM, etc).. We have no etiologic driver of the RPGN in terms of standard vasculitis or autoimmune testing.  On immunosuppressives.
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Abnormal behaviour, Chills, Dizziness, Dysstasia, Fatigue
Clinical narrative: fever 102F Chills Dizziness, Staginess. Couldn't stand without holding anything. tiredness.
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: fever 102F Chills Dizziness, Staginess. Couldn't stand without holding anything. tiredness.
Age: 73.0
Sex: F
Vaccine: COVID19, FLU4
Symptoms: Atrial fibrillation, Cardioversion, Hypotension, Shock
Clinical narrative: New onset atrial fibrillation with rapid ventricular response associated with hypotension and shock
Age: 61.0
Sex: M
Vaccine: COVID19-2
Symptoms: Anosmia, Nasal discharge discolouration, Rhinorrhoea
Clinical narrative: Patient reported to me over a year from the date of administration that about a week after the vaccine he started to develop fluorescent green snot that lasted about 9 months as well as a loss of smell.  Patient told me that he reported it to the PCP, but PCP wasn't concerned.  I advised the patient that it was probably a case of Covid-19 that occurred about the same and not related to the vaccine, but did tell patient I would report it as a possible vaccine related event.
Age: 28.0
Sex: M
Vaccine: COVID19
Symptoms: Skin disorder
Clinical narrative: Developed a skin condition resembling psoriasis on my arms and legs and groin 2 weeks after my second shot that has never gone away since (now 2023).
Age: 45.0
Sex: F
Vaccine: FLU4
Symptoms: Chills, Erythema, Injection site cellulitis, Injection site irritation, Injection site reaction
Clinical narrative: swelled up the size of a grapefruit, red, warm, body aches, body chills, fever of 100.1, pain/sore
Age: 45.0
Sex: F
Vaccine: FLU4
Symptoms: Pain, Pyrexia, Skin warm, Swelling
Clinical narrative: swelled up the size of a grapefruit, red, warm, body aches, body chills, fever of 100.1, pain/sore
Age: 54.0
Sex: F
Vaccine: COVID19-2
Symptoms: Dizziness, Hot flush, Nausea, Pain, Syncope
Clinical narrative: Hot flashes. Nausea, Body aches light headed  Synscope
Age: 8.0
Sex: F
Vaccine: FLUN4
Symptoms: Erythema, Swelling face, Urticaria, Vomiting
Clinical narrative: Mom states that a couple hours after getting Flumist, Child developed vomiting.  The next morning she was covered in hives.  Mom gave Benedryl and Xyzal.    Mom called 11/01/2023 at 2 PM to request Flumist be added to her allergy list.  Child was scheduled to be seen in office 11/02/2023 around 11 AM.  Mom reports that on the morning of 11/02/2023 Child had facial swelling.  Patient was given a dose of benadryl and xyzal prior to appointment and continued to have mild redness of skin.  No fever or vomiting.
Age: 89.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Cough, Decreased appetite, Dyspnoea, Pneumonia
Clinical narrative: to ED c/o cough, SOB, weakness, decreased appetite, +pneumonia; TX: zinc, singulair, decadron, remdesivir, rocephine, zithromax, lovenox. D/C'd to home
Age: 0.75
Sex: M
Vaccine: DTAPHEPBIP, HEPA, PNC20
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: Hepatitis A vaccine given to a child under age 1 year